Pathological Significance and Prognostic Role of Microvessel Density, Evaluated Using CD31, CD34, and CD105 in Prostate Cancer Patients After Radical Prostatectomy with Neoadjuvant Therapy

Overview

Journal Prostate

Date 2014 Oct 14

PMID 25307287

Citations 39

Authors

Yasuyoshi Miyata

Kensuke Mitsunari

Akihiro Asai

Kosuke Takehara

Yasushi Mochizuki

Hideki Sakai

Affiliations

Soon will be listed here.

Abstract

Background: Neoadjuvant hormonal therapy (NHT) is performed to improve the outcome in organ-confined prostate cancer. However, there is little information regarding the relationship between angiogenesis and NHT. The aim of this study was to identify a suitable method to evaluate the angiogenic status of tissue, and to determine the prognostic value of this method for biochemical recurrence in patients who had undergone radical prostatectomy after NHT.

Methods: We analyzed 108 formalin-fixed specimens from patients treated by radical prostatectomy. NHT was administered in 48 patients (52.9%) and 60 patients who had a similar Gleason score and pT stage were selected as a non-NHT treated control group. Microvessel density (MVD) was measured using anti-CD31, anti-CD34, and anti-CD105 antibodies. The expressions of vascular endothelial growth factor (VEGF)-A and thrombospondin (TSP)-1 were also evaluated by immunohistochemistry. The prognostic value of CD31-, CD34-, and CD105-MVD for biochemical recurrence was investigated.

Results: The mean/SD of CD105-MVD in the NHT group (13.3/4.7) was significantly (P < 0.001) lower than that in the non-NHT group (125.8/7.3). In the NHT group, CD105-MVD was associated with pT stage and it was positively correlated with VEGF-A expression (r = 0.56, P < 0.001) and negatively correlated with TSP-1 expression (r = 0.42, P = 0.003). CD105-MVD was identified as a significant predictor of biochemical recurrence (BCR) in patients treated with NHT (log rank test, P < 0.001). Although CD31- and CD34-MVD were significantly associated with pT stage or Gleason score in non-NHT group, they were not associated with pathological features and BCR in NHT group.

Conclusions: Our results indicate that CD105-MVD reflects the angiogenic conditions in prostate cancer tissues treated with NHT. CD105-MVD was also identified as a significant and independent predictor of biochemical recurrence in prostate cancer patients who underwent radical prostatectomy with NHT.

Citing Articles

Evidence of the Link between Stroma Remodeling and Prostate Cancer Prognosis.

Vecchiotti D, Clementi L, Cornacchia E, Di Vito Nolfi M, Verzella D, Capece D Cancers (Basel). 2024; 16(18).

PMID: 39335188 PMC: 11430343. DOI: 10.3390/cancers16183215.

Deep learning-based automated pipeline for blood vessel detection and distribution analysis in multiplexed prostate cancer images.

Karageorgos G, Cho S, McDonough E, Chadwick C, Ghose S, Owens J Front Bioinform. 2024; 3:1296667.

PMID: 38323039 PMC: 10844485. DOI: 10.3389/fbinf.2023.1296667.

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.

Huang Y, Cuan X, Zhu W, Yang X, Zhao Y, Sheng J Int J Mol Sci. 2023; 24(18).

PMID: 37762316 PMC: 10531337. DOI: 10.3390/ijms241814012.

The role of tumor model in magnetic targeting of magnetosomes and ultramagnetic liposomes.

Curcio A, Perez J, Preveral S, Fromain A, Genevois C, Michel A Sci Rep. 2023; 13(1):2278.

PMID: 36755030 PMC: 9908874. DOI: 10.1038/s41598-023-28914-4.

TNF Signaling Is Required for Castration-Induced Vascular Damage Preceding Prostate Cancer Regression.

Krolewski J, Singh S, Sha K, Jaiswal N, Turowski S, Pan C Cancers (Basel). 2022; 14(24).

PMID: 36551505 PMC: 9775958. DOI: 10.3390/cancers14246020.

References

Stewart R, Panigrahy D, Flynn E, Folkman J . Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol. 2001; 165(2):688-93. DOI: 10.1097/00005392-200102000-00095. View

Fitchev P, Wcislak S, Lee C, Bergh A, Brendler C, Stellmach V . Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. Lab Invest. 2010; 90(7):1078-90. PMC: 3055786. DOI: 10.1038/labinvest.2010.90. View

WATSON R, Civantos F, Soloway M . Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology. 1996; 48(1):80-90. DOI: 10.1016/s0090-4295(96)00092-1. View

Miyata Y, Ohba K, Matsuo T, Watanabe S, Hayashi T, Sakai H . Tumor-associated stromal cells expressing E-prostanoid 2 or 3 receptors in prostate cancer: correlation with tumor aggressiveness and outcome by angiogenesis and lymphangiogenesis. Urology. 2012; 81(1):136-42. DOI: 10.1016/j.urology.2012.08.014. View

Joseph I, Nelson J, Denmeade S, Isaacs J . Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1998; 3(12 Pt 1):2507-11. View

Kumar P, Wang J, Bernabeu C . CD 105 and angiogenesis. J Pathol. 1996; 178(4):363-6. DOI: 10.1002/(SICI)1096-9896(199604)178:4<363::AID-PATH491>3.0.CO;2-8. View

Aslan G, Cimen S, Yorukoglu K, Tuna B, Sonmez D, Mungan U . Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract. 2005; 201(8-9):593-8. DOI: 10.1016/j.prp.2005.07.003. View

Ryan C, Smith A, Lal P, Satagopan J, Reuter V, Scardino P . Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology. 2006; 68(4):834-9. DOI: 10.1016/j.urology.2006.04.016. View

Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A . Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res. 2005; 65(1):300-8. View

10.

Eisermann K, Broderick C, Bazarov A, Moazam M, Fraizer G . Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer. 2013; 12:7. PMC: 3616929. DOI: 10.1186/1476-4598-12-7. View

11.

Tesan Tomic T, Gustavsson H, Wang W, Jennbacken K, Welen K, Damber J . Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Prostate. 2011; 72(7):705-12. DOI: 10.1002/pros.21472. View

12.

Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K . Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer. 1999; 85(8):1822-7. DOI: 10.1002/(sici)1097-0142(19990415)85:8<1822::aid-cncr24>3.0.co;2-1. View

13.

Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M . Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol. 2009; 28(6):687-92. DOI: 10.1007/s00345-009-0471-4. View

14.

Cheng L, Zhang S, Sweeney C, Kao C, Gardner T, Eble J . Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res. 2004; 24(4):2135-40. View

15.

Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M . Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 2001; 7(11):3410-5. View

16.

Sato F, Fukuhara H, Basilion J . Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo. Neoplasia. 2005; 7(9):838-46. PMC: 1501932. DOI: 10.1593/neo.05145. View

17.

Joseph I, Isaacs J . Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res. 1997; 57(6):1054-7. View

18.

Bettencourt M, Bauer J, Sesterhenn I, Connelly R, Moul J . CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol. 1998; 160(2):459-65. View

19.

Miyata Y, Sagara Y, Watanabe S, Asai A, Matsuo T, Ohba K . CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34. Virchows Arch. 2013; 463(5):673-9. PMC: 3825622. DOI: 10.1007/s00428-013-1463-8. View

20.

Rubatt J, Darcy K, Hutson A, Bean S, Havrilesky L, Grace L . Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol. 2009; 112(3):469-74. DOI: 10.1016/j.ygyno.2008.11.030. View